Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis
GMS Infectious Diseases · 30.03.2022 · 10 (Doc02) · Doc02-Doc02
DOI: 10.3205/id000079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift GMS Infectious Diseases, erschienen am 30.03.2022. Verfasst von Alexandra Ehrens und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Filarial diseases like lymphatic filariasis and onchocerciasis belong to the Neglected Tropical Diseases and remain a public health problem in endemic countries. Lymphatic filariasis and onchocerciasis can lead to stigmatizing pathologies and present a socio-economic burden for affected people and their endemic countries. Current treatment recommendations by the WHO include mass drug administration with ivermectin for the treatment of onchocerciasis and a combination of ivermectin, albendazole and diethylcarbamazine (DEC) for the treatment of lymphatic filariasis in areas that are not co-endemic for onchocerciasis or loiasis. Limitations of these treatment strategies are due to potential severe adverse events in onchocerciasis and loiasis patients following DEC or ivermectin treatment, respectively, the lack of a macrofilaricidal efficacy of those drugs and the risk of drug resistance development. Thus, to achieve the elimination of transmission of onchocerciasis and the elimination of lymphatic filariasis as a public health problem by 2030, the WHO defined in its roadmap that new alternative treatment strategies with macrofilaricidal compounds are required. Within a collaboration of the non-profit organizations Drugs for Neglected Diseases initiative (DNDi), the Bill & Melinda Gates Foundation, and partners from academia and industry, several new promising macrofilaricidal drug candidates were identified, which will be discussed in this review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany.
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany.
Zitieren
APA
Ehrens, A., Hoerauf, A., & Hübner, M. P. (2022). Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis. GMS Infectious Diseases, 10(Doc02), Doc02-Doc02. https://doi.org/10.3205/id000079
Vancouver
Ehrens A, Hoerauf A, Hübner MP. Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis. GMS Infectious Diseases. 2022;10(Doc02):Doc02-Doc02. doi:10.3205/id000079
BibTeX
@article{Ehrens2022,
author = {Ehrens, Alexandra and Hoerauf, Achim and Hübner, Marc P},
title = {Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis},
journal = {GMS Infectious Diseases},
year = {2022},
volume = {10},
number = {Doc02},
pages = {Doc02--Doc02},
doi = {10.3205/id000079}
}
EUVIMED